Select Page

Grifols’s Prolastina approved for use in Denmark

Jan 29, 2020 | News

The Alpha-1 Foundation is proud to report that multinational pharmaceutical manufacturer Grifols also received approval by the Danish Medicines Council for Prolastina, a plasma-derived drug used for augmentation therapy.

The Danish Medicines Council, citing a reasonable relationship between the value of the drug and the cost of treatment, recommended that human alpha-1 antitrypsin plasma-based therapy become the standard treatment for severe Alpha-1 Antitrypsin Deficiency (AATD). The Council approved two products for treatment: Respreeza® and Prolastina.

Based on the recent publication from the Health Policy Journal (Sundhedspolitisk Tidsskrift) and the Danish Medicines Council, the following information was communicated to the global community:

The recommendation is applicable to patients who have progressive emphysema and documented smoking cessation that must be present for at least six months prior to initiation of treatment, as well as progressive emphysema when detected by CT scan has documented emphysema with concomitant pulmonary function.

Treatment requires an annual reassessment, and is discontinued if the patient meets any of the following criteria:

  • receives a single or double lung transplant.
  • terminal diagnosis is assessed, and continued treatment is therefore deemed futile or too demanding for the patient.
  • resumes smoking. This can be checked by carbon monoxide measurement prior to each injection patients being treated in hospital. For patients who self-administer treatment at home, for example, cotinine measurement every 6 months can be used.
  • is not considered to have sufficient effect on the treatment. Loss of lung density of more than 30g / L within 10 years of treatment should cease treatment

Alpha-1 antitrypsin is derived from human plasma and is given to increase the plasma concentration of alpha-1 antitrypsin in patients with severe Alpha-1 Antitrypsin Deficiency and evidence of progressive emphysema. The treatment is given to delay the development of emphysema and the drug is given as maintenance treatment and at 60 mg/kg body weight once weekly by intravenous infusion.

Source: Sundhedspolitisk Tidsskrift and The Medicines Council

Alpha-1 Events Calendar

June

July 2020

August
S
M
T
W
T
F
S
28
29
30
1
2
3
4
Events for July

1st

No Events
Events for July

2nd

No Events
Events for July

3rd

No Events
Events for July

4th

No Events
5
6
7
8
9
10
11
Events for July

5th

No Events
Events for July

6th

No Events
Events for July

7th

No Events
Events for July

8th

No Events
Events for July

9th

No Events
Events for July

10th

No Events
Events for July

11th

12
13
14
15
16
17
18
Events for July

12th

No Events
Events for July

13th

No Events
Events for July

14th

No Events
Events for July

15th

No Events
Events for July

16th

No Events
Events for July

17th

No Events
Events for July

18th

No Events
19
20
21
22
23
24
25
Events for July

19th

No Events
Events for July

20th

No Events
Events for July

21st

No Events
Events for July

22nd

No Events
Events for July

23rd

No Events
Events for July

24th

No Events
Events for July

25th

No Events
26
27
28
29
30
31
1
Events for July

26th

No Events
Events for July

27th

No Events
Events for July

28th

No Events
Events for July

29th

No Events
Events for July

30th

No Events
Events for July

31st

No Events